Theoretical and Computational Chemistry

Potential 2019-nCoV 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches


The emergence of the 2019 novel coronavirus (2019-nCoV), for which there is no vaccine or any known effective treatment created a sense of urgency for novel drug discovery approaches. One of the most important 2019-nCoV protein targets is the 3C-like protease for which the crystal structure is known. Most of the immediate efforts are focused on drug repurposing of known clinically-approved drugs and virtual screening for the molecules available from chemical libraries that may not work well. For example, the IC50 of lopinavir, an HIV protease inhibitor, against the 3C-like protease is approximately 50 micromolar. In an attempt to address this challenge, on January 28th, 2020 Insilico Medicine decided to utilize a part of its generative chemistry pipeline to design novel drug-like inhibitors of 2019-nCoV and started generation on January 30th. It utilized three of its previously validated generative chemistry approaches: crystal-derived pocked- based generator, homology modelling-based generation, and ligand-based generation. Novel druglike compounds generated using these approaches are being published at and will be continuously updated. Several molecules will be synthesized and tested using the internal resources; however, the team is seeking collaborations to synthesize, test, and, if needed, optimize the published molecules.


Thumbnail image of Insilico Medicine Generative Sprint 2019-nCoV Project.pdf
download asset Insilico Medicine Generative Sprint 2019-nCoV Project.pdf 1 MB [opens in a new tab]

Supplementary material

Thumbnail image of INSCoV-2020 sdf v1.txt
download asset INSCoV-2020 sdf v1.txt 0.40 MB [opens in a new tab]
INSCoV-2020 sdf v1

Supplementary weblinks